Hal Barron (GSK via YouTube)
Year-end earnings show turbulent times for Hal Barron's GlaxoSmithKline turnaround
Hal Barron and Emma Walmsley’s big GlaxoSmithKline pivot may ultimately prove successful, delivering blockbusters in cancer, auto-immune conditions and infectious disease. But the path to get there is already looking rocky.
GSK announced their year-end earnings Wednesday morning, revealing that they had cut two more pipeline candidates after they failed in early stage trials and disappointing investors with news that profits had fallen and earnings per share would decline by mid to high single digits.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters